LDL-cholesterol reduction in chronic kidney disease: options beyond statins

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Chronic kidney disease (CKD) significantly elevates the risk of atherosclerotic cardiovascular disease (ASCVD).
• Low-density lipoprotein cholesterol (LDL-C) is a primary modifiable risk factor for ASCVD.
• Statins are effective in reducing ASCVD events in CKD populations.

Purpose of the Study:

• To review the efficacy and safety of novel non-statin LDL-C-lowering therapies for patients with CKD.
• To evaluate the role of emerging treatments in managing cardiovascular risk in this vulnerable population.

Main Methods:

• Review of current literature on non-statin lipid-lowering agents.
• Analysis of clinical trial data and guidelines regarding ezetimibe and PCSK9 inhibitors in CKD.
• Assessment of safety profiles, efficacy in LDL-C reduction, and administration routes.

Main Results:

• Ezetimibe safely reduces LDL-C by 15-20% in CKD patients.
• PCSK9 inhibitors (monoclonal antibodies and inclisiran) achieve 50-60% LDL-C reduction.
• PCSK9 therapies require no dose adjustment in CKD and have no drug interactions, though outcome trials for inclisiran are pending.

Conclusions:

• Statins and ezetimibe are established safe options for ASCVD risk reduction in CKD.
• PCSK9 targeting therapies represent a promising option for high-risk CKD patients, particularly those with established ASCVD.